Given the very rare frequency of APP, PSEN1, and PSEN2 pathogenic mutations detected in the screened patients (two individuals with EOAD), our hypothesis should encourage genetic screening in larger cohorts of both EOAD and LOAD, as well as dementia cases using the gene panel. This evidence concerns the gene PSEN2 and dementia.